Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - kalcipotriol hidrat betametazondipropionat - mast - 50 mikrograma/g + 500 mikrograma/g - urbroj: 1 g masti sadrži 50 mikrograma kalcipotriola (u obliku hidrata) i 0,5 mg betametazona (u obliku dipropionata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - amoksicilin trihidrat - kapsula, tvrda - 500 mg - urbroj: jedna tvrda kapsula sadrži 500 mg amoksicilina u obliku amoksicilin trihidrata

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanmed d.o.o. banja luka - ampicilin - prašak za rastvor za injekciju - 1 g/1 viala - 1 bočica sa praškom za rastvor za injekciju sadrži: 1 g ampicilin (u obliku ampicilinnatrijuma)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanmed d.o.o. banja luka - amoksicilin, klavulanska kiselina - prašak za rastvor za injekciju/infuziju - 1000 mg/1 viala+ 200 mg/1 viala - 1,2 g praška za rastvor za injekciju/infuziju sadrži: 1000 mg amoksicilina 200 mg klavulanske kiseline

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - metotreksat - rastvor za injekciju u napunjenoj šprici - 20 mg/1 ml - 1 ml rastvora za injekciju sadrži: 20 mg metotreksata (u obliku 21,94 mg dinatrijevog metotreksata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - kalcipotriol hidrat betametazondipropionat - gel - 50 µg/g + 0,5 mg/g - urbroj: jedan gram gela sadrži 50 mikrograma kalcipotriola (u obliku hidrata) i 0,5 mg betametazona (u obliku dipropionata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - betametazondipropionat salicilatna kiselina - mast - 0,5 mg/g + 30 mg/g - urbroj: jedan gram masti sadrži 0,5 mg betametazona u obliku betametazondipropionata i 30 mg salicilatne kiseline

Europska Unija - hrvatski - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - imunosupresivi - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti (vidi odjeljak 5. 1) i poboljšati tjelesne funkcije. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 i 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psorijaza - imunosupresivi - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psorijaza - imunosupresivi - treatment of moderate-to-severe plaque psoriasis in adults.